Low-Dose Imaging for Early Multi-disease Assessment & Prevention
- Aug 7
- 1 min read
Low-Dose Imaging for Early Multi-disease Assessment & Prevention is a nonprofit initiative established to advance one of the most ambitious preventive medicine programs ever proposed: the LDCT Mega Trial. The initiative envisions using a single low-dose, non-contrast CT scan combined with artificial intelligence to detect multiple life-threatening diseases before symptoms develop, fundamentally transforming the way preventive healthcare is delivered.
The proposed LDCT Mega Trial plans to enroll 100,000 participants to evaluate whether AI-assisted low-dose CT screening can reduce mortality from cardiovascular disease, lung cancer, COPD, metabolic disorders, osteoporosis, and other chronic conditions through earlier detection and personalized preventive care. Rather than focusing on a single disease, the study introduces a comprehensive multi-disease screening strategy designed to maximize the clinical value of every CT examination.
Beyond the scientific vision, this presentation outlines the organizational framework of confenernce, including its nonprofit mission, trial governance, fundraising strategy, philanthropic partnerships, and long-term public health goals. The initiative aims to create an open, collaborative platform where researchers, clinicians, policymakers, and philanthropic organizations work together to establish new global standards for AI-enabled preventive medicine and equitable access to early detection.
This presentation presents the vision, clinical rationale, trial design, implementation roadmap, and philanthropic strategy behind this conference, illustrating how a single low-dose CT scan could become the foundation of population-scale, AI-driven preventive healthcare.
Download the complete presentation below to explore the confenernce vision, LDCT Mega Trial design, nonprofit strategy, and roadmap toward the future of preventive medicine.
Comments